Who Should Avoid Superpower: Specific Patient Profiles and an Honest Review

What Is Superpower and How Does the Model Work?

Superpower markets itself as a "proactive health" subscription that bundles comprehensive biomarker labs, async or synchronous clinician review, and optional prescriptions for GLP-1 receptor agonists and peptides into a single monthly fee. The pitch targets patients who feel underserved by primary care and want data-driven optimization rather than reactive sick-care.

The model is not unique. Several telehealth platforms, including Hims & Hers, LifeMD, and Ro, operate variations of this structure. What distinguishes Superpower's marketing is an emphasis on peptide protocols (BPC-157, TB-500, CJC-1295/Ipamorelin, PT-141) alongside the better-studied GLP-1 agents. That combination raises regulatory and safety questions that a single monthly fee does not resolve.

How Prescriptions Are Issued

Prescriptions are issued by clinicians licensed in the patient's state after an online intake form and, in most cases, a telehealth visit. The depth of that evaluation matters. A 20-minute async review of a lab panel is not equivalent to a face-to-face history and physical.

Compounding Pharmacy Relationships

Superpower, like many GLP-1 telehealth platforms, has relied on 503A or 503B compounding pharmacies for semaglutide and tirzepatide. The FDA placed semaglutide on its shortage list and later removed it in 2024, triggering a phase-out of compounded versions. As of early 2025, the FDA confirmed that compounded semaglutide from 503A pharmacies may no longer be dispensed for most patients [1]. Any platform still offering compounded semaglutide after that date warrants scrutiny.

Is Superpower Legit?

Superpower operates as a licensed telehealth company with real clinicians issuing real prescriptions. That makes it legally distinct from fraudulent online pharmacies. The more precise question is whether the oversight model is appropriate for your clinical complexity.

LegitScript and State Licensing

LegitScript is the primary third-party certification body for online pharmacies and telehealth prescribers in the United States. Patients should confirm current LegitScript status at legitscript.com before enrolling, because certification can lapse. The FDA's guidance on internet pharmacies states that legitimate dispensers should always require a valid prescription from a licensed practitioner who has conducted a proper patient evaluation [2].

BBB Complaints and Consumer Reports

The Better Business Bureau (BBB) profile for subscription telehealth companies routinely shows billing and cancellation complaints. Common patterns reported for Superpower and similar services include difficulty canceling memberships, unexpected charges after trial periods, and delays in prescription fulfillment. These are operational rather than clinical concerns, but they matter when you are managing a chronic therapy like a GLP-1 that requires uninterrupted dosing.

Peptide Regulatory Status

Peptides such as BPC-157, TB-500, and CJC-1295/Ipamorelin are not FDA-approved drugs. The FDA has issued warning letters to compounding pharmacies producing peptides outside approved pathways [3]. Prescribing these compounds through a telehealth subscription does not confer FDA approval. Patients should understand they are accepting off-label or unapproved-compound risk when they order these agents.

Patient Profiles Who Should Avoid Superpower

This is the section most telehealth brand reviews skip. The following profiles represent patients whose clinical complexity, safety risk, or behavioral health needs exceed what an async subscription model can safely manage.

Profile 1: Personal or Family History of Medullary Thyroid Carcinoma or MEN2

GLP-1 receptor agonists carry an FDA Boxed Warning for thyroid C-cell tumors. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [4]. Rodent studies showed dose-dependent thyroid C-cell tumors with liraglutide and semaglutide, and while causality in humans is not established, the contraindication stands across the drug class.

A subscription intake form that relies on self-reported history may not catch a patient who does not know their family history includes MTC. An in-person clinician with access to family records and the ability to palpate the thyroid is better positioned to screen this risk.

Profile 2: Active Eating Disorders

Active anorexia nervosa, bulimia nervosa, or binge-eating disorder with active compensatory behaviors represent a population for whom GLP-1-induced appetite suppression and nausea may be destabilizing rather than therapeutic. The American Psychiatric Association's practice guidelines note that weight-loss interventions in patients with active eating disorders require integrated psychiatric co-management [5].

A telehealth subscription does not typically include a psychiatric intake screening that is sensitive enough to detect subclinical eating pathology. Patients with a current or recent eating disorder diagnosis should engage a multidisciplinary team, not an async concierge.

Profile 3: Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)

Semaglutide is primarily eliminated via general protein catabolism, not renal excretion, so dose adjustment is not mandated by pharmacokinetics alone. However, GLP-1 agents cause nausea, vomiting, and reduced oral intake. In patients with chronic kidney disease stage 4 or 5, dehydration from GI side effects can precipitate acute kidney injury on chronic kidney disease [6]. The Prescribing Information for Wegovy specifically notes postmarketing reports of acute kidney injury, including cases requiring dialysis [4].

Patients with eGFR <30 mL/min/1.73 m² should have nephrology co-management. A telehealth subscription is not structured to coordinate that care.

Profile 4: History of Pancreatitis

Acute and chronic pancreatitis have been reported with GLP-1 receptor agonists in postmarketing surveillance. The FDA label for semaglutide states the drug should be discontinued if pancreatitis is confirmed, and it should be used with caution in patients with a history of pancreatitis [4]. A patient with recurrent pancreatitis from hypertriglyceridemia, alcohol use, or gallstone disease is not an appropriate candidate for unsupervised GLP-1 prescribing through an async model.

Profile 5: Complex Polypharmacy or Drug-Drug Interaction Risk

GLP-1 agents delay gastric emptying. For patients on narrow therapeutic index drugs, including warfarin, levothyroxine, and certain antiepileptics, that delay may alter absorption enough to affect therapeutic levels [7]. A clinician reviewing a patient's medication list through a telehealth intake form may not systematically screen for all interaction risks. Patients on three or more chronic medications should have a pharmacist-level drug interaction review before starting a GLP-1.

Profile 6: Gallbladder Disease

Rapid weight loss from GLP-1 therapy accelerates cholesterol gallstone formation. The STEP-1 trial (N=1,961) showed that cholelithiasis occurred in 1.6% of semaglutide 2.4 mg patients versus 0.7% of placebo patients at 68 weeks [8]. Patients with known cholelithiasis or a prior cholecystectomy complicated by bile duct issues should disclose this history and discuss risk with a gastroenterologist, not only a telehealth prescriber.

Profile 7: Pregnancy, Planning Pregnancy, or Breastfeeding

Semaglutide and tirzepatide are Pregnancy Category X equivalents under current labeling. Animal studies show fetal harm at clinically relevant exposures. The prescribing information for Wegovy states patients should discontinue at least 2 months before a planned pregnancy [4]. Women of reproductive age should be counseled on contraception before starting these agents. An async subscription model may not reliably deliver that counseling.

Profile 8: Patients Seeking Peptides Without Understanding the Evidence Gap

BPC-157 and TB-500 have no completed Phase II or Phase III human trials. The mechanistic data come from rodent studies. A 2023 review in the Journal of Orthopaedic Research noted that while animal data for BPC-157 in tendon healing appear promising, no randomized controlled trials in humans have been completed [9]. A patient enrolling in Superpower's peptide protocol to treat a specific injury should understand they are not receiving an evidence-based treatment, and they bear the full informational burden of that decision.

Superpower Complaints: What the Pattern Reveals

Consumer complaint data is not peer-reviewed, but patterns across multiple platforms provide signal. Recurring themes in reviews of Superpower and comparable services include the following.

Billing and Cancellation Disputes

Subscription telehealth companies generate a disproportionate share of their BBB complaints around billing. Monthly membership fees continue after patients stop using the service, and cancellation processes are often multi-step. This matters clinically because patients who stop using the platform may also stop receiving prescription renewals for chronic therapies.

Prescription Fulfillment Delays

Compounding pharmacy pipelines for GLP-1 agents have been stressed since 2023 due to the nationwide shortage. Patients on a fixed monthly injection schedule cannot tolerate 2-to-3-week gaps in supply without clinical consequence. At least one peer-reviewed analysis of GLP-1 discontinuation noted that stopping semaglutide results in weight regain of approximately two-thirds of lost weight within 1 year [10].

Clinician Continuity

Async models do not guarantee the same clinician sees your follow-up labs and adjusts your dose. Lack of continuity is a known risk factor for suboptimal titration and missed adverse event signals.

What GLP-1 Clinical Trials Actually Show

Understanding the trial data helps patients evaluate whether the promises embedded in Superpower's marketing match the evidence.

STEP-1 Trial: Semaglutide 2.4 mg

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% for placebo (P<0.001) [8]. The trial required a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity. These are the approved criteria. Telehealth platforms prescribing GLP-1 agents to patients below these thresholds are operating outside label.

SURMOUNT-1 Trial: Tirzepatide

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% for placebo [11]. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023 based in part on these data.

The SELECT Trial: Cardiovascular Benefit

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in overweight or obese patients with established cardiovascular disease but without diabetes, over a mean follow-up of 39.8 months [12]. This is now a meaningful prescribing consideration beyond weight alone, and the FDA approved the cardiovascular indication for Wegovy in March 2024.

What to Ask Before Enrolling in Any GLP-1 Subscription Service

A patient considering Superpower or any similar platform should be able to get clear answers to the following questions before paying.

Prescriber Qualifications and Continuity

Ask whether the prescriber reviewing your labs holds board certification in internal medicine, endocrinology, or obesity medicine. Ask whether the same provider will manage your follow-up doses.

Pharmacy Accreditation

Ask which pharmacy fulfills prescriptions and whether it holds PCAB accreditation or is a registered 503B outsourcing facility. The FDA's database of registered outsourcing facilities is publicly searchable [13].

Protocol for Adverse Events

Ask what the escalation path is if you develop pancreatitis symptoms, severe nausea requiring IV hydration, or injection site reactions. If the answer is "contact your local ER," the platform is not equipped to manage the therapy it prescribes.

Peptide Informed Consent

For peptide protocols, ask whether informed consent documentation explicitly states that these compounds are not FDA-approved and that long-term safety data in humans are not available.

Regulatory and Safety Field for Telehealth GLP-1 Prescribing

The FDA's Center for Drug Evaluation and Research (CDER) has issued multiple communications about compounded GLP-1 agents. A February 2025 FDA statement confirmed that once FDA-approved versions of a drug are available in adequate quantities, compounded versions lose their legal status under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act [1]. Platforms continuing to supply compounded semaglutide after this determination are doing so outside FDA guidance.

The Federal Trade Commission (FTC) has also increased scrutiny of subscription health services for deceptive billing practices under Section 5 of the FTC Act. Patients who experience unauthorized charges may file complaints at ftc.gov/complaint.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Pharmacological treatment of obesity should be provided by clinicians with expertise in obesity medicine who can deliver comprehensive care, including behavioral support and monitoring for adverse effects." [14] A subscription app that emails you a dose titration schedule is not "comprehensive care" as the Endocrine Society defines it.

When Superpower May Be Appropriate

Not every patient needs specialist-level oversight. For a healthy adult with a BMI of 32, no significant comorbidities, no relevant medication interactions, no family history of MTC, and the financial means to pay out of pocket, a GLP-1 subscription service may provide access that traditional primary care does not.

The evidence base for GLP-1 therapy is strong. STEP-1 and SURMOUNT-1 demonstrate clinically meaningful weight loss. SELECT shows cardiovascular benefit. The drug class is legitimate. The question is always whether the prescribing and monitoring infrastructure matches the patient's complexity.

Low-complexity profiles where a service like Superpower may be a reasonable option include: adults with BMI of 30 or higher, no active psychiatric illness, no chronic kidney disease, no active GI disease, no narrow-therapeutic-index polypharmacy, and reliable access to emergency care if needed.